Overbought Stocks
ABSI appears in our Overbought Stocks screen, meaning it has experienced strong recent gains and may be trading at extended levels that could lead to short-term consolidation or pullback.
ABSCI CORP (ABSI) Stock Price & Overview
NASDAQ:ABSI • US00091E1091
Current stock price
4.86 USD
+0.01 (+0.21%)
At close:
4.83 USD
-0.03 (-0.62%)
After Hours:
The current stock price of ABSI is 4.86 USD. Today ABSI is up by 0.21%. In the past month the price increased by 76.09%. In the past year, price increased by 60.4%.
ABSI Key Statistics
52-Week Range2.24 - 5.228
Current ABSI stock price positioned within its 52-week range.
1-Month Range2.8 - 5.04
Current ABSI stock price positioned within its 1-month range.
- Market Cap
- 743.677M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.85
- Dividend Yield
- N/A
ABSI Stock Performance
Today
+0.21%
1 Week
+24.62%
1 Month
+76.09%
3 Months
+62.54%
Longer-term
6 Months +13.55%
1 Year +60.40%
2 Years +2.53%
3 Years +268.18%
5 Years N/A
10 Years N/A
ABSI Stock Chart
ABSI Stock Screens
ABSI currently appears in the following ChartMill screener lists.
ABSI Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ABSI. When comparing the yearly performance of all stocks, ABSI is one of the better performing stocks in the market, outperforming 92.54% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ABSI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABSI. No worries on liquidiy or solvency for ABSI as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ABSI Earnings
On March 24, 2026 ABSI reported an EPS of -0.2 and a revenue of 650.00K. The company missed EPS expectations (-0.92% surprise) and missed revenue expectations (-42.07% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateMar 24, 2026
PeriodQ4 / 2025
EPS Reported-$0.20
Revenue Reported650K
EPS Surprise -0.92%
Revenue Surprise -42.07%
ABSI Forecast & Estimates
15 analysts have analysed ABSI and the average price target is 8.19 USD. This implies a price increase of 68.5% is expected in the next year compared to the current price of 4.86.
For the next year, analysts expect an EPS growth of 1.26% and a revenue growth 76.24% for ABSI
Analysts
Analysts81.33
Price Target8.19 (68.52%)
EPS Next Y1.26%
Revenue Next Year76.24%
ABSI Groups
Sector & Classification
ABSI Financial Highlights
Over the last trailing twelve months ABSI reported a non-GAAP Earnings per Share(EPS) of -0.85. The EPS increased by 8.6% compared to the year before.
Income Statements
Revenue(TTM)2.80M
Net Income(TTM)-115.18M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.25% | ||
| ROE | -60.8% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%20%
Sales Q2Q%-2.26%
EPS 1Y (TTM)8.6%
Revenue 1Y (TTM)-38.24%
ABSI Ownership
Ownership
Inst Owners76.34%
Shares153.02M
Float132.28M
Ins Owners6.57%
Short Float %26.52%
Short Ratio8.73
ABSI Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.33 | 349.118B | ||
| AMGN | AMGEN INC | 14.87 | 183.592B | ||
| GILD | GILEAD SCIENCES INC | 14.62 | 158.566B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.08 | 108.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.61 | 78.702B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.26 | 41.165B | ||
| INSM | INSMED INC | N/A | 29.351B | ||
| NTRA | NATERA INC | N/A | 28.968B | ||
| BIIB | BIOGEN INC | 11.37 | 26.515B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.093B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.47 | 24.851B | ||
| MRNA | MODERNA INC | N/A | 19.314B | ||
| INCY | INCYTE CORP | 12.63 | 19.048B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ABSI
Company Profile
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 156 full-time employees. The company went IPO on 2021-07-22. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. The company has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Company Info
IPO: 2021-07-22
ABSCI CORP
18105 Se Mill Plain Blvd
Vancouver Washington WASHINGTON US
CEO: Sean McClain
Employees: 156
Phone: 13026587581
ABSCI CORP / ABSI FAQ
What does ABSCI CORP do?
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 156 full-time employees. The company went IPO on 2021-07-22. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. The company has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
What is the stock price of ABSCI CORP today?
The current stock price of ABSI is 4.86 USD. The price increased by 0.21% in the last trading session.
What is the dividend status of ABSCI CORP?
ABSI does not pay a dividend.
What is the ChartMill rating of ABSCI CORP stock?
ABSI has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is ABSCI CORP worth?
ABSCI CORP (ABSI) has a market capitalization of 743.68M USD. This makes ABSI a Small Cap stock.
Who owns ABSCI CORP?
You can find the ownership structure of ABSCI CORP (ABSI) on the Ownership tab.
What is the Short Interest ratio of ABSCI CORP (ABSI) stock?
The outstanding short interest for ABSCI CORP (ABSI) is 26.52% of its float.